Dr. Holger Hofmeister advises corporate clients and private equity firms in connection with acquisitions, divestitures, public takeovers, joint ventures, and other M&A and corporate matters, including capital markets-related issues. In addition, he advises on corporate governance-related matters and corporate restructurings.


Dr. Hofmeister’s representative matters include advising, among others:

  • Airbnb, Inc. in its acquisition of Germany-based fewoVista S.L. & Co. KG and Vacaleo GmbH;
  • Apax Partners in connection with:
    • its proposed US$8.5 billion bid for ISS/AS, a facilities management provider, from Goldman Sachs Capital Partners and EQT Partners AB; and
    • the US$420 million sale of Versatel AG, a provider of telecommunications and information technology services, to Kohlberg Kravis Roberts & Co., a private equity firm;
  • Braskem S.A. in its US$323 million acquisition of the polypropylene business from The Dow Chemical Company;
  • Daimler AG in connection with various matters including:
    • the carve-out and disposals of Daimler dealerships throughout Germany, Belgium and Luxembourg;
    • projects relating to the cooperation with Renault-Nissan-Alliance;
    • various real estate disposals;
    • the sale of its subsidiary Russ & Janot GmbH to Lei Shing Hong Limited, a Hong Kong-based company engaged in automobile and heavy machinery distribution;
    • the sale of its subsidiary Taunus-Auto-Verkaufs GmbH to KBM Motorfahrzeuge GmbH & Co. KG, a German automobile and heavy machinery distributor; and
    • the divestiture of its worldwide Chrysler distribution business;
  • Dürr AG, a major German industrial machinery group, in connection with:
    • several M&A transactions including the acquisition of iTAC Software AG; and
    • the formation of the joint venture ADAMOS (ADAptive Manufacturing Open Solutions) with Software AG, an enterprise software company; DMG Mori, a machine tool manufacturer; optical group Zeiss; and ASM PT, a tool manufacturer of circuit boards;
  • Fresenius SE & Co. KGaA, a health care company in Germany, in the sale of Fresenius Biotech GmbH to the Fuhrer family, owners of Neopharm Ltd., a pharmaceutical company;
  • Hillenbrand, Inc., a holding company for a funeral products manufacturer and an industrial equipment supplier, in its:
    • definitive agreement to acquire Abel GmbH & Co. KG, a manufacturer of inter alia diaphragm pumps and certain of its affiliates from Roper Technologies, Inc., a diversified technology company, for €95 million in cash; and
    • US$530 million acquisition of Coperion GmbH, a manufacturer of industrial machinery and plants, from Deutsche Beteiligungs AG, a private equity firm;
  • Hamburg Commercial Bank (f/k/a HSH Nordbank) in connection with its privatization and related matters, including the sale of a loan portfolio;
  • IAC/InterActive Corp in its acquisition of a majority shareholding in MyHammer Holding AG from Holtzbrinck Digital GmbH and the subsequent voluntary takeover;
  • KAP-Beteiligungs-Aktiengesellschaft in its public takeover by a subsidiary of The Carlyle Group and in connection with several M&A transactions;
  • Koenigsegg Group in the proposed acquisition of Saab, the Swedish auto manufacturer, from General Motors;
  • Konecranes Plc in its US$1.5 billion acquisition of Terex Corporation’s material handling and port solutions business segment;
  • LANXESS AG, a global specialty chemicals company, in its US$2.5 billion all-cash acquisition of Chemtura Corporation;
  • Merck KGaA, a biotechnology and pharmaceutical company, a distributor of laboratory products, and a manufacturer of specialty chemicals, food additives and cosmetics, in connection with:
    • its €13.8 billion all-cash acquisition of Sigma-Aldrich Corporation and in the divestiture of certain business of Merck/Sigma-Aldrich to obtain antitrust clearance for such acquisition; and
    • the US$6.7 billion sale of its worldwide generic drugs business to Mylan Laboratories, Inc. Prior to sale, the business underwent a significant reorganization with a number of related carve-out transactions to separate the generics business from the remaining Merck group;
  • Odewald & Compagnie, a private equity firm, in its acquisition of Oberberg Kliniken, an operator of mental health clinics;
  • Quadriga Capital in connection with various M&A transactions, including the sale (together with Barclays Private Equity) of Jack Wolfskin GmbH, a manufacturer and retailer of sportswear and apparel, to The Blackstone Group, L.P.;
  • Süd-Chemie AG in the formation of a US$300 million joint venture with Ashland Inc. to merge their foundry chemicals businesses under the name of ASK Chemicals GmbH;
  • Telegraaf Media Groep N.V. in the sale of its interest in SBS Broadcasting and its option to purchase a minority stake in ProSiebenSat.1 Media AG;
  • TPV Technology Limited in the proposed acquisition of a 70 percent interest in a joint venture, which will own and control the entire television business of Koninklijke Philips Electronics N.V. in Europe and certain South American countries;
  • Vue Entertainment Ltd. in its acquisition of CinemaxX AG from Dr. Herbert Kloiber, Dr. Kloiber Vermögensverwaltungsgesellschaft mbH & Co. Beteiligungs KG and other shareholders; and
  • WABCO Holdings Inc. in its US$7 billion acquisition by ZF Friedrichshafen AG.



  • Dr. Jur., University of Regensburg, 1999
  • Second State Exam, Appellate Court of Duesseldorf, 2001
  • First State Exam, University of Regensburg, 1998


  • Frankfurt am Main

Holger Hofmeister